Daniel M. Jorgensen, MD, MPH, MBA

Dr. Daniel Jorgensen is an accomplished physician executive with ~26 years of experience in the
biopharmaceutical industry, in both small and large companies, public and private, including C-level
positions for the past ~13 years. He is currently Special Advisor and former CEO of the Critical Path
Institute (C-Path). In these roles, Dr. Jorgensen has worked closely with a broad range of investors,
strategic partners, and scientific experts, while building exceptional teams. His background includes
comprehensive research, development, and commercialization experience for small molecules,
biologics/vaccines, and devices across multiple therapeutic areas, particularly infectious diseases,
immunology/inflammation, diabetes, and neuroscience. During his 10 years at Pfizer, Dr. Jorgensen was
the Global Clinical Leader for azithromycin and was named Pfizer’s first Vaccine Development Team
Leader, playing a key role in multiple FDA meetings, submissions, and approvals. Prior to joining
Industry, he was an Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control &
Prevention (CDC), focusing on infectious disease outbreaks, vaccine accessibility, and refugee health,
and thereafter, held several public health leadership positions, including Montana State Medical Officer.
Dr. Jorgensen was educated at Yale (BS); University of Wisconsin (MD); University of Washington (MPH);
and Yale (MBA), with specialty training in Pediatrics, Infectious Diseases, and Preventive Medicine.